Disappointment in Heart Health: Pelacarsen Drug Fails in Trials

In a recent clinical trial, an experimental cholesterol drug known as pelacarsen has failed to deliver on its potential to reduce the risk of heart attacks and strokes. This outcome has left researchers in shock, marking a significant setback for preventative cardiology.

Key Findings of the Trial

The results of the Horizon trial were unveiled at the American Heart Association's annual meeting. Researchers were dismayed to find no measurable improvements in heart health among participants taking pelacarsen, an injection aimed at lowering lipoprotein(a) or Lp(a) — a genetically driven form of cholesterol linked to cardiovascular diseases. Dr. Amanda Doran from Vanderbilt University Medical Center, a site for the trial, voiced the disappointment saying, "I really thought that this was going to be a slam dunk."

Despite pelacarsen achieving an impressive reduction of Lp(a) levels by 78% compared to a placebo's 13%, this did not translate into fewer heart attacks, strokes, or cardiovascular-related deaths.

The Participants and Their Conditions

The Horizon trial involved 8,322 individuals who had high levels of Lp(a) and had encountered heart issues, such as previous heart attacks or strokes, in the last decade. The participants, with an average age of 60 years, were closely monitored over an average period of five years.

Dr. Steven Nissen, who led the trial at the Cleveland Clinic, expressed his surprise at the lack of positive outcomes. “There is simply no evidence that people who had a greater reduction did any better,” he remarked, reflecting the broader sentiment of confusion among experts.

Why Pelacarsen Didn't Work

Several hypotheses have been proposed to explain the unexpected results. Some experts believe that the timing of treatment could have played a role, suggesting that for genetics-based issues like Lp(a), intervening late in life might not yield noticeable benefits. The aggressive treatment of other risk factors—such as LDL cholesterol and blood pressure—could have also obscured any potential positive effects of lowering Lp(a) levels, as noted by Dr. Karol Watson from UCLA.

Additionally, study participants might have been on preventative therapies like aspirin, which may have reduced the clotting risks associated with Lp(a). “How much of the Lp(a) risk remained in this well-treated population? We can only speculate,” Dr. Watson pointed out.

The Importance of Lp(a) Screening

Even amidst the disappointing findings, Lp(a) remains an important focus for cardiology. High levels of Lp(a) are still a significant indicator of cardiovascular risk, leading the American Heart Association to recommend that every adult gets their levels tested. Understanding one’s Lp(a) status could prompt more aggressive preventive measures, deemed crucial for those with elevated levels.

Dr. John Wilkins from Northwestern Medicine emphasized that the failure of pelacarsen does not diminish the significance of Lp(a) as a heart disease risk marker. It remains essential for identifying individuals at a higher risk for cardiovascular events, thereby allowing for timely interventions.

Looking Ahead: Future Treatments for Lp(a)

Despite the setback with pelacarsen, researchers remain optimistic about alternative approaches to dealing with high Lp(a). There are several other medications in development, such as Eli Lilly’s lepodisiran and Amgen’s olpasiran, both targeting the liver's production of Lp(a) through different mechanisms. Clinical trials for these treatments are ongoing, and early reporting suggests potential advantages over pelacarsen.

Moreover, advancements in gene-editing technologies are also in the early stages, aiming to directly modify the gene responsible for producing Lp(a). While pelacarsen may not have achieved the desired outcomes, the ongoing research provides hope that effective treatments will eventually emerge. Dr. Doran concluded, “I’m still so hopeful that we will eventually find a solution.”